GlaxoSmithKline pharmaceuticals S.A. In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your entire professional career to GlaxoSmithKline (GSK), that you joined in 1992. What has kept you within the group, what has…
polski holding farmaceutyczny (PHF) Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was to privatise the three entities. You joined in March 2008, at a time when, if I may say, major steps…
Polpharma SA For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to the benefit of MNCs. How has the arrival of GSK, Teva or Sandoz, altered the playing field for the company…
Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…
Johnson&Johnson Romania In order to provide our readers with a general idea of the current state of the Romanian pharmaceutical and healthcare sectors, can you first of all elaborate on the key particularities of this market? Romania has been a member of the EU since 2009, is a potential member of the…
INFARMA Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and become an attractive market for innovators. Could you give us an idea of how the market for innovative drugs has…
Roemmers Roemmers fue establecida en 1921. ¿Cómo paso de ser una empresa familiar a la empresa que es hoy, y cuáles han sido los desafíos en el cambio en la cultura de la empresa? La crisis económica que sufrió Argentina en 2002, sirvió como catalizador para un cambio radical en Roemmers,…
Octapharma Brazil Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could you delve a bit deeper and elaborate on this point? Before delving into the Brazilian market situation, it is important…
Česká asociace farmaceutických firem (ČAFF) Dr. Zörner, can you please begin by introducing our readers to the CAFF (Czech Association of Pharmaceutical Firms), and explicate its key activities and mission? We represent 24 companies in the Czech pharmaceutical industry that are mainly involved in the generics business. Our mission is to promote the generics industry,…
Pharmaceutical Manufacturers Association of Turkey (IEIS) IEIS is an association with dual responsibilities. Promotion of generic usage in turkey and ensuring the sustained development of a local manufacturing industry. Before we look into these two aspects, I would like you to give us your perspective on the future role of the association, in an environment where…
MSD Mexico We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes you feel strong enough to continue growing in Mexico.” Can you please explain the thinking behind this statement, and what…
Industria Farmacéutica Andrómaco First of all, can you tell us about the history of Andromaco and what have been its major milestones and challenges over the years? This year marks the eightieth anniversary of Andromaco in Mexico. The company was founded by my grandfather, Fernando Rubió, and his business partner Raul Roviralta in…
See our Cookie Privacy Policy Here
